prikaz prve stranice dokumenta Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
Journal of Neuroimmunology, 382 (2023); 578164. https://doi.org/10.1016/j.jneuroim.2023.578164
Adamec, Ivan; Brecl Jakob, Gregor; Rajda, Cecilia; Drulović, Jelena; Radulović, Ljiljana; Bašić Kes, Vanja; Lazibat, Ines; Rimac, Julija; Cindrić, Igor; Gržinčić, Tihana; Abičić, Ana; Barun, Barbara; Gabelić, Tereza; Gomezelj, Sarah; Mesaroš, Šarlota; Pekmezović, Tatjana; Klivényi, Péter; Krbot Skorić, Magdalena; Habek, Mario Više autora...

Citirajte ovaj rad

Adamec, I., Brecl Jakob, G., Rajda, C., Drulović, J., Radulović, Lj., Bašić Kes, V. ... Habek, M. (2023). Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of Neuroimmunology, 382.. doi: 10.1016/j.jneuroim.2023.578164

Adamec, Ivan, et al. "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers." Journal of Neuroimmunology, vol. 382, 2023. https://doi.org/10.1016/j.jneuroim.2023.578164

Adamec, Ivan, Gregor Brecl Jakob, Cecilia Rajda, Jelena Drulović, Ljiljana Radulović, Vanja Bašić Kes, Ines Lazibat, et al. "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers." Journal of Neuroimmunology 382 (2023). https://doi.org/10.1016/j.jneuroim.2023.578164

Adamec, I., et al. (2023) 'Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers', Journal of Neuroimmunology, 382. doi: 10.1016/j.jneuroim.2023.578164

Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović Lj, Bašić Kes V, i sur.. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of Neuroimmunology [Internet]. 09.2023. [pristupljeno 26.10.2024.];382. doi: 10.1016/j.jneuroim.2023.578164

I. Adamec, et al., "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers", Journal of Neuroimmunology, vol. 382, Rujan 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:430848. [Citirano: 26.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:430848
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
AutorIvan Adamec
AutorGregor Brecl Jakob
AutorCecilia Rajda
AutorJelena Drulović
AutorLjiljana Radulović
MBZ: 74741
AutorVanja Bašić Kes
AutorInes Lazibat
AutorJulija Rimac
AutorIgor Cindrić
AutorTihana Gržinčić
AutorAna Abičić
AutorBarbara Barun
AutorTereza Gabelić
AutorSarah Gomezelj
AutorŠarlota Mesaroš
AutorTatjana Pekmezović
AutorPéter Klivényi
AutorMagdalena Krbot Skorić
AutorMario Habek
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Background: Cladribine is an oral disease-modifying drug authorized by the European Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS). Objectives: To provide real-world evidence of cladribine’s effectiveness and safety in people with MS (pwMS). Methods: A retrospective observational multi-center, multi-national study of pwMS who were started on cladribine tablets in ten centers from five European countries. Results: We identified 320 pwMS treated with cladribine tablets. The most common comorbidities were arterial hypertension and depression. Three patients had resolved hepatitis B infection, while eight had positive Quantiferon test prior to cladribine commencement. There were six pwMS who had malignant diseases, but all were non-active. During year 1, 91.6% pwMS did not have EDSS worsening, 86.9% were relapse-free and 72.9% did not have MRI activity. During the second year, 90.2% did not experience EDSS worsening, 86.5% were relapse-free and 75.5% did not have MRI activity. NEDA-3 was present in 58.0% pwMS in year 1 and in 54.2% in year 2. In a multivariable logistic regression model age positively predicted NEDA-3 in year 1. The most common adverse events were infections and skin-related adverse events. Lymphopenia was noted in 54.7% of pwMS at month 2 and in 35.0% at month 6. Two pwMS had a newly discovered malignant disease, one breast cancer, and one melanoma, during the first year of treatment. Conclusion: Our real-world data on the effectiveness and safety of cladribine tablets are comparable to the pivotal study and other real-world data with no new safety signals.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Neuroimmunology
Brojčani podacivol. 382, 578164
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2023.578164
URN:NBNurn:nbn:hr:220:430848
Datum objave publikacije2023-09
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0165572823001509
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-06-24 10:28:31